CAR-T Cellular Therapy Development


CAR-T Cellular Therapy Solutions

From optimizing CAR-T cell design and evaluating pre-clinical models to discovering response biomarkers and mechanisms of action, together we can advance the field of cellular therapy and improve the human condition.


See All Publications

Therapeutically expanded human regulatory T-cells are super-suppressive due to HIF1A induced expression of CD73.

The adoptive transfer of regulatory T-cells (Tregs) is a promising therapeutic approach in transplantation and autoimmunity. However, because large cell numbers are needed to achieve a therapeutic effect, in vitro expansion is required.

CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial.

Chimeric antigen receptor (CAR) T cells targeting CD19 or CD22 have shown remarkable activity in B cell acute lymphoblastic leukemia (B-ALL). The major cause of treatment failure is antigen downregulation or loss.

A novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy applications.

Background aims: Next-generation immune cell therapy products will require complex modifications using engineering technologies that can maintain high levels of cell functionality. Non-viral engineering methods have the potential to address limitations associated with viral vectors.

Spotlight on CAR-T

Webinar New Approaches for CAR-T Cell Therapies: Technology Symposium featuring GeoMx spatial profiling and nCounter CAR-T Characterization
Webinar Murine March Madness: Contextual reprogramming of CAR-T cells for the treatment of HER2-expressing cancers
Blog Q&A with Dr. Lisa Butterfield, PhD: Cancer Vaccines & Adoptive Cell Transfer
Blog SITC in Focus: CAR-T Cell Therapy
Poster Molecular Characterization for CAR-T Cell Therapy-Poster

Related Resources

View All Resources
Product Bulletin CAR-T Characterization Panel – Product Bulletin
Blog Q&A with Dr. Lisa Butterfield, PhD: Cancer Vaccines & Adoptive Cell Transfer
Blog SITC in Focus: CAR-T Cell Therapy
Poster CAR-T EU Congress 2019 Poster – A Step Toward Standardization with the nCounter® CAR-T Characterization Panel
Product Bulletin nCounter® Stem Cell Characterization Panel Product Bulletin

Contact Us

Have questions or simply want to learn more?

Contact our helpful experts and we’ll be in touch soon.

Contact Us